IL6 and breast cancer: In contrast with that in the CON treatment, contents of the serum proinflammatory factors (TNF-α, IL-1β, IL-6) in the BC and LA treatments were reduced evidently (P < 0.05, Figures 5A,C,D), and the TNF-α and IL-1β contents in the BC treatment were lower than those in the LA treatment (P < 0.05, Figures 5A,C).